Back to today’s briefing

Story perspectives

Acadia Halts ACP-101 Trial, Shares Plummet 11%

9/25/2025

50 6

Summary

Story summary

Acadia Pharmaceuticals halted ACP-101 after a 12-week Phase 3 Prader-Willi trial with 175 patients failed to meet the primary endpoint.
Acadia shares fell about 11%, while Soleno Therapeutics rose about 13%.
Soleno's Vykat XR remains the only FDA-approved hyperphagia treatment with strong sales.
Analysts had low expectations for ACP-101; Acadia will pivot to other pipeline assets and existing-product revenue.

1 of 1

Story summary

Acadia Pharmaceuticals halted ACP-101 after a 12-week Phase 3 Prader-Willi trial with 175 patients failed to meet the primary endpoint.
Acadia shares fell about 11%, while Soleno Therapeutics rose about 13%.
Soleno's Vykat XR remains the only FDA-approved hyperphagia treatment with strong sales.
Analysts had low expectations for ACP-101; Acadia will pivot to other pipeline assets and existing-product revenue.